International Research Journal of Innovations in Engineering and Technology - IRJIET International Open Access, Monthly, Peer Reviewed, Reputed Journal ISSN (online): 2581-3048

Impact Factor (2025): 6.9

DOI Prefix: 10.47001/IRJIET

Enhancing Drug Safety: AIs Role in Pharmacovigilance and Adverse Event Reporting

Hannah AlexSchool of Pharmacy, University of Pittsburgh, USA

Vol 8 No 9 (2024): Volume 8, Issue 9, September 2024 | Pages: 194-197

International Research Journal of Innovations in Engineering and Technology

OPEN ACCESS | Research Article | Published Date: 26-09-2024

doi Logo doi.org/10.47001/IRJIET/2024.809024

pdf iconFull Text PDF
Abstract

The role of pharmacovigilance (PV) in healthcare is to optimize the safety and efficacy of the delivery of pharmaceutical drugs and medical equipment. The increasingly dynamic nature of adverse drug reactions and pharmacovigilance has rendered traditional approaches susceptible to the underreporting of ADRs.  Subsequently, the integration of Artificial intelligence in adverse drug reaction reporting is an outstanding technological advancement in pharmacovigilance. Therefore, this critical analysis applied a systematic literature review to comprehend the extensive role of AI in Pharmacovigilance. The research findings acknowledged that AI technologies such as machine learning, deep learning, and natural learning processing (NLP) have automated PV, leading to enhanced signal detection, analysis of unstructured data, risk assessment, and regulatory compliance.

Keywords

Pharmacovigilance (PV), natural learning processing, adverse drug reactions (ADR), signal detection, deep learning, Artificial intelligence, and machine learning


Citation of this Article

Hannah Alex. (2024). Enhancing Drug Safety: AIs Role in Pharmacovigilance and Adverse Event Reporting. International Research Journal of Innovations in Engineering and Technology - IRJIET, 8(9), 194-197. Article DOI https://doi.org/10.47001/IRJIET/2024.809024

Licence Copyright (c) 2026 International Research Journal of Innovations in Engineering and Technology creative common licence This work is licensed under Creative common Attribution Non Commercial 4.0 Internation Licence
References
  1. Bate, Andrew, and Jens-Ulrich Stegmann. "Artificial intelligence and pharmacovigilance: What is happening, what could happen and what should happen?" Health Policy and Technology 12.2, (2023): 100743.
  2. Beninger, Paul, et al. "Effects of the Covid-19 pandemic on pharmacovigilance strategy, systems, and processes of large, medium, and small companies: An industry survey." Clinical Therapeutics 44.9 (2022): 1225-1236.
  3. Caster, Ola, et al. "Large‐scale regression‐based pattern discovery: The example of screening the WHO global drug safety database." Statistical Analysis and Data Mining: The ASA Data Science Journal 3.4 (2010): 197-208.
  4. Comfort, Shaun, et al. "Sorting through the safety data haystack: using machine learning to identify individual case safety reports in social-digital media." Drug Safety 41 (2018): 579-590.
  5. Crooks, Colin John, David Prieto-Merino, and Stephen JW Evans. "Identifying adverse events of vaccines using a Bayesian method of medically guided information sharing." Drug Safety 35 (2012): 61-78.
  6. Harerimana, Gaspard, et al. "Deep learning for electronic health records analytics." IEEE Access 7 (2019): 101245-101259.
  7. Jokinen, Jeremy, et al. "Industry assessment of the contribution of patient support programs, market research programs, and social media to patient safety." Therapeutic Innovation & Regulatory Science 53.6 (2019): 736-745.
  8. Lee, Inyoung, et al. "Impact of adverse event reports from marketing authorization holder-sponsored patient support programs on the performance of signal detection in pharmacovigilance." Expert Opinion on Drug Safety 19.10 (2020): 1357-1366.
  9. Luo, Yuan, et al. "Natural language processing for EHR-based pharmacovigilance: a structured review." Drug Safety 40 (2017): 1075-1089.
  10. Mouffak, Amelle, et al. "High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: A meta-epidemiological study." Journal of Clinical Epidemiology, 138 (2021): 73–79.
  11. Patel K, et al. "Artificial intelligence is changing the face of Pharmacovigilance." Pharmacy Times, 17 Oct. 2022, www.pharmacytimes.com/view/artificial-intelligence-is-changing-the-face-of-pharmacovigilance.
  12. Powell, Greg, et al. "Engaging patients via online healthcare fora: Three pharmacovigilance use cases." Frontiers in Pharmacology 13 2022: 901355.
  13. Sessa, Maurizio, et al. "Artificial intelligence in pharmacoepidemiology: A systematic review. part 2–comparison of the performance of artificial intelligence and traditional pharmacoepidemiological techniques." Frontiers in Pharmacology 11 (2021): 568659.
  14. Stergiopoulos, Stella, et al. "Adverse drug reaction case safety practices in large biopharmaceutical organizations from 2007 to 2017: An industry survey." Pharmaceutical Medicine 33.6 (2019): 499-510.
  15. Silver K. "The future of Pharmacovigilance: Applying AI and other tech to monitor medicine and vaccine safety | Pfizer." Pfizer: One of the world's premier biopharmaceutical companies, 2024, www.pfizer.com/news/articles/the_future_of_pharmacovigilance_monitoring_medicine_and_vaccine_safety_using_ai_and_other_tech.
  16. Upadhyay, Jyoti, Mukesh Nandave, and Anoop Kumar. "Role of Artificial Intelligence in Pharmacovigilance." Pharmacovigilance Essentials: Advances, Challenges and Global Perspectives. Singapore: Springer Nature Singapore, 2024. 347-363.
  17. Vickers-Smith, Rachel, et al. "Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system." Drug and Alcohol Dependence, 206 (2020): 107709.
  18. Wang, Shirley V., Sushama Kattinakere Sreedhara, and Sebastian Schneeweiss. "Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions." Nature Communications 13.1 (2022): 5126.

Copyright @ 2026 IRJIET. All Right Reserved.

Licensed underCreative Commons Attribution 4.0 International License.